secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2023-04-26T23:59:59+00:00
Accession:  0001645113-23-000036
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure LUNAR phase 3 NSCLC trial met primary endpoint; results at ASCO 2023
-----------------------------------------------------------------------------

- LUNAR trial showed statistically significant improvement in overall survival with TTFields plus standard therapies in metastatic NSCLC.
- Full results to be presented as a late-breaking abstract at ASCO 2023 on June 6, 2023, at 11:09 a.m. CDT.
- Novocure will host an investor event on June 6 at 2 p.m. CDT to discuss the data.
- First phase 3 trial evaluating TTFields outside the brain and with immunotherapy.
- Ten abstracts on TTFields therapy, including LUNAR, will be presented at ASCO 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000036/0001645113-23-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000036/nvcr-20230426.htm
  HTML page:      https://secwatch.observer/filing/0001645113-23-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer